Corcept Therapeutics (CORT) said Thursday the phase 2 trial of its experimental therapy, dazucorilant, did not meet its primary endpoint, sending shares down 1.4% in premarket activity.
Dazucorilant is intended to treat amyotrophic lateral sclerosis, a fatal motor neuron disease.
The company said the study showed that therapy did not meet its primary endpoint of improved outcome in the ALS functional rating scale-revised in patients who received dazucorilant compared to patients who received placebo.
However, no deaths occurred in the patient group receiving 300 mg of dazucorilant compared to five deaths in the placebo group, the company said, adding that an exploratory one-year analysis also demonstrated continued survival benefit, especially for those who stayed on 300 mg for over 24 weeks.
The long-term extension study is still ongoing, the company added.
Price: 68.99, Change: -0.99, Percent Change: -1.41
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。